Cutting-edge biotech ideas need refined hypothesis & proof of concept for early resources & funds.
see Disclaimer
Cutting-edge biotech ideas need refined hypothesis & proof of concept for early resources & funds.
see Disclaimer
What is "considered" more likely to be a "success" ... depends on whom is doing the considering, and how they define success. Because survival rates are low (about 1 in 9) and time to profit is typically long (5 to 7 years), persons willing to help are very selective. Who matters in defining success are those who provide key elements for success (funders, key scientist-founder with outstanding concept, resource providers and top consultant).
They define success as ventures which will survive, get a product or discovery to market-license (or cure) faster, fill a large market demand, and make large profits (or licensing).
To compensate for many dead ends--- the few successes must be outstanding with $billions potential.
Though we also help scientists and corporations, we prefer ventures with large potential (for Founders or Funders).
First, it takes high knowledge, experience and credentials (PhD, MS, or Corporate executive, VC, Angel) or being wealthy. Regardless, a PhD scientist must assess scientific rationale and help oversee or be a lab/project manager. Some are able to hire Top scientists required to execute a Life Science or Biotech venture... without major restarts or pivots.
Few people should try to run, own or even enter as a minor partner a business in which they are not highly-familiar; That is especially true for ventures based on advanced science/ technology.
The ability to select what would be competitive, and who could implement it... is often not well done even by experts in the field, such as Life science venture funds, or Corporate management with years in the field.
Unless you have massive wealth to invest years of support in an expensive venture, you might be better off being selective in the stock market, and possibly hiring one of our USA TopPhD-Consultant scientists to help you research opportunities, the same way any smart VC, Angel or Investment Banker should. See our Funders page.
Both biotech and life science ventures, institutes and projects require:
All this requires money, skill, experience and resources. Such tough requirements are
positives for a business (once started). as "barriers to competition" (to entry).
Venture fund-capitalists, investment bankers, securities lawyers-- likely will NOT tell you why or how to delay using them, how to not assign everything to the new company early, how to not lose control, and not assume onerous duties:
YOU Should:
This requires you to have an open mind, read and learn, and probably a minimum of about $60,000^ to start (mostly to hire and partly-barter for a lab and Top scientist) (not all your money)
^ depends on difficulty of experiments (any medical or pharma-related, likely more)
If you are a science-entrepreneur but don't have patience to learn some business/ strategy/ownership details--- you probably should think hard about what to do, or generally be ready to go with the flow of what funders and your lawyer tell you (expect to retain less control and ownership).
The life science and biotech market is wide open, ready...for wins, takeovers and turnarounds.
Too much money chases weakly-managed, poorly-staffed ventures. Major progress is seldom. R&D times are too long. Production costs are too high. The market niches are many, dominated by one to three companies / institutes. Staffing is often twice or more what is required.
There are good reasons why a large proportion of biotech startups fail within 5 years. Many are forced to "pivot" (reorient) their business. As selective as funders/ VC's are, (3% of proposals considered, only 0.3% funded), you'd think they could do much better.
THEY should, by using Top USA-consultants to help select projects.
VC's do rate PhD-led proposals higher (which are 1/4th they receive), so.. . Get one!
Your "pitch" and proposal will stand out when it provides what they will see that they need. It's about clarity, priorities, proof of concept and credibility (an expert to vouch).
Whenever a field is a) new, b) complex, c) difficult to enter (barriers to entry).. .
there's usually weak competition, few with high efficiency, easily "snowing" the industry and investors but "being first", pivoting... claiming-- then "owning" a large niche.
That's your competition or customers.
The niche leaders become entrenched. Inertia, bureaucracy and even social policies often take over. This happens in new, growth fields/ technologies. (think computers, internet bubble, telecom, solar, EV's, AI. A shakeout follows)
You... your project... your consultant... must stand out as real, practical, heavy-duty, advanced, serving a big under-served niche, with exceptional value, ratios, metrics, efficiency (profits).
So, great management, market niche selectivity, hiring top USA A-school PhD scientist-talent (first as consultants, perhaps granting small "groud-floor equity" (stock)) or royalties and knowing how to motivate, build teams, set correct priorities, hire the best and "knowing the business" and HOW to start--- make the difference.
Giving top talent and sources of resources a "piece of the action" (an interest by royalty, stock, small options (caution-options may be securities)--- motivates.
CAUTION: regulated "securities may be involved for any but royalties (usually), short term loans, and small "partnering" (S-corporate/ LLC) by "sophisticated" (SEC definition) investors. (Anything like an ESOP or profit sharing plan requires Lawyers and CPA's (expensive) so might be pushed to much later).
In all cases of sales and exchanges of stock, (except royalties), risk disclosures, participants knowledgable in the business, and limiting to less than 10% of worth is required. For royalties, a similar standard, if perhaps not required, should apply (a good idea), regardless. Grants of stock, may or may not be regulated (ask a lawyer).
SEEK COMPETENT PROFESSIONAL LEGAL and FINANCIAL ADVICE.
Your use of this website and/or Consultant constitutes and signifies your acceptance and agreement to all the terms in Disclaimers in this website:
--> DO YOUR OWN DUE DILIGENCE. SEE DISCLAIMER AT BOTTOM:
These pages may contain errors and -->may entirely not be suitable for your situation.
Do not rely solely on the information in this website.
It is general-informational, not advice for your specific situation.
None of the information here is guaranteed. Confirm and do your own due diligence.
We operate at the intersection of
a) new projects*, b) innovation & c) predictive deep science ...
to vet, design proof of concept experiments, and help make concepts do-able, efficient and (hopefully) scalable.
*(ventures, businesses, spin-offs, institutes)
We...
Focus on: correct science, standards, good planning, productivity, scalability.
Analysis for: scientists, investors/funders, executives/managers who oversee life science operations. (not financial advice),
Monitor labs and projects; Review or investigate research, hypotheses for validity, potential and scalability. We troubleshoot labs and monitor adherence to standards.
Aid strategy and corporate development.
Aid performance and efficiency alongside life science innovators.
Aid: seed stage, start ups, expansion, turnarounds, spin-offs, acquisitions, strategic partnering-- by performing Research & Development, overseeing standards, protocols & projects;
We can help fill interim direct management.
Science focus: on proteins, enzymes, mRNA control/adaption, bioengineering, custom protein engineering, AI 3D cells imaging, lung and prostate cancer research, science prior art review, meta research, statistical analysis, efficiency and scalability. We have experience in diagnostics, biologics/ therapeutics, cell and cancer development-imaging.
Help investors find and evaluate life-science/ biotech innovations for investments, using broad knowledge and experience; Expert opinion to suggest potential innovations to consider.
Have high communication and organizational skills, experience, solid education, often
using higher math to Interpret and quantify complex concepts and ideas into digestible content for key persons, stakeholders.
Coordinae organizational teams.
Provide expert analysis of large datasets common in biosciences, assisting solutions to unique and complex life science issues.
Assist managers on improving efficiency, developing new products and services, utilizing deep science predictive principles with emerging technologies, equipment.
for Project duration: typically 2 weeks to 8 months, usually small companies or spin-offs of 2 to 400 employees.
The future does not come from broad mediocrity, but from excellence: a few brilliant leaders and minds--- building bright collaborative teams, integrating various skills, concepts and technologies.
Our consultants know high level techniques to refine concepts and hypotheses, working as "perfection assistants" to design proof of concept to aid presentations and funding, and helping find best approaches while avoiding dead ends, pivots, potential dangers and wasted time.
Our experts work on concept assessment, proof, research and developing cellular therapies, biologics, bioengineering, processes for a variety of needs and conditions, as well as developmental biology, genetic methods, protein and enzyme science and various other core competencies , skills and technologies. Well-versed in cutting-edge techniques, tools and instruments to discover innovations, techniques and methods with high potential.
Our bioengineering, molecular biophysics and lab techniques often improve results. We help set up labs, help with QA and QC, and can help troublshoot or oversee aspects of a lab or process that can make a critical difference in results and outcomes. Setting out lab goals and projects, establishing protocols, data recording, trade secret security, and quality standards--- helps avoid mis-starts and wasted time and money. The future belongs to the quick, smart and productive.
Though much of this site is oriented to Scientist-entrepreneurs, our Consultants also assist Scientists, Corporations, Grantors and Investors/ Funding groups.
If you are not primarily an entrepreneur, check out the above links to pages that apply.
There is some overlap, so good information can be gleaned throughout.
If you are experienced, you know some of the pitfalls, risks and obstacles to taking a breakthrough to wide application, licensing or commercial exploitation.
If you are new to creating a successful project, venture, institute, spin-off, innovation lab or powerhouse corporation around a disruptive product/process--- then there are scores of caveats and risks to consider. Study and hire some good help.
This difference in culture of these environments can be devastating to the uninitiated academic.
To Venture Capitalists and Angels and Investment bankers- the novice academic is often a "babe in the woods" (not quite a sheep to be sheared) and presents a higher risk.
The practices and culture of academics sometimes disqualify the capable scientist, due to the habits of sharing, group/team efforts, publishing, public discussion. These may condemn a concept at the inception, for Funders. It must be secret. MOST of it.
The sheer cost of a biotech project, even at the pre-seed stage--- is a barrier to thousands of great ideas--- the lack of a "proof of concept" experiment, especially. VC's are seldom interested in just "a great idea". Or, a grant team member may demand you get a partner or some "resources". Most highly-value a patent. We suggest caution on that.
SEE our page on IP-Secrets-NonDisclosure
At early stages, either of these "requirements" present large risks to a potentially hugely-valuable trade secret. Powerful funders can be short sighted--- for YOUR interests. They often hold all the power. They want proven value "security" of valuable IP "assets" signed over to the company. (A government grant team member likely comes from academia and is not cautious about, nor versed in-- trade secrets).
It's time to learn a little about "deal-making", entrepreneur interests-goals, and secrecy.
(by interests we mean your legal rights/ power/ownership/ control)
Even if the VC's-investors are interested after some proof is offered, your mistakes of publicity, publishing, prior cooperation or work agreement, etc. or seeking a partner lab the wrong way--- may destroy the value. (If all this seems too difficult/ makes you uncomfortable or discouraged--- then you may not be "successful entrepreneur material." But frankly, these concepts are not that hard, are right here and on the internet, to reach out, pluck, confirm and use. You simply have to decide and "man (or woman) up".).
If you pass these hurdles, since most scientists don't start an institute, spin-off or disruptive company or division (under a large corporation)--- under the conventional approach, the VC or investment banker and lawyers not only require their 18% (average) of funds raised, but by the last "milestone"/round (4-6)--- have often taken and sold about 60 to 70% ownership and most control from the Founder-Creator (you). You'll likely not own or control the key IP.
They consider that IP the main asset, along with expertise--- of the company... the "value" they sell to investors. So they insist on assigning ownership of IP, or at least rights to get it before major funding.
These are only some of the obstacles and hazards you are up against.
Consider hiring "knights" to champion your cause and help you keep as much ownership as possible as long as possible.
None of the "big guys" in funding are going to talk you out of using--- mainly them.
Eventually, for big money, you will likely have to go that route, but you might keep others from taking more than 40-60% if you try alternatives and learn how to get "further along" early, without selling too much (by exchanges for resources, securing key secrets longer, etc.), or promising valuable sellable "product" within 2 years (if you can).
Funders and VC's actually prefer that you have also proven some ability to "execute"
(get well into pre-seed or seed stage)--- before risking investors funds on you.
But know that if too early you try to "stand up", being different (not want to immediately assign all the IP to the funded company)... you'll not likely get an audience with the "king makers". But there are many VC's and big companies to approach.
The decision and how long to "hold out" depends on knowing if you have a "world beater"---
a "Wow" invention/concept: High Demand, High Margins, Big Market, Little competition, Barriers to competition, Scalability.
THAT, my friend, nearly ALWAYS interests a smart Funder (if you have credibility and proof of concept). Then... when they learn you may have some other Investment Bankers possibley wanting it... "the Earth shifts"... and YOU are in charge.
It is then a matter of "structuring the deal" , preferably so they get early return (not having to wait 7 years) and a commitment from the concept owner to eventually sell or license (not assign), the key trade secret(s) when high profitability is reached.
The real kicker would be telling them that (if true) that "payback" and big profits (maybe dividends) begin within 2-3 years.♦
♦ VC's usually must wait 3 or 4 years for pre-seed and development, with high risk, so any quicker, more-certain results WILL get their attention and interest.
An argument against early patent or assignment, is that early patent or disclosure (even to the/your new company they fund) risks opening attempts to copy or steal the secrets; About $10 million in reserve is needed to complete patents and have a legal war-chest ready to defend.
Your knowledge, the large value of your secret and your fierceness on keeping/ defending/ controlling the secrecy until some MCI (money coming in) will not put you in bad stead with the right VC/ Investment banker, but may decrease odds of finding one.
A lot of people are rigid. Look for one who is not. (Likewise your attorney/advisor).
If you have already disclosed too much, you might recover by finding a different aspect or improvement that otherwise the "invention" or process is impractical without.
This is where a Top outside PhD consultant may help improve or modify the process or product to meet the real world obstacles and demands of "scalability" and efficiency.
Thereby, your prior "partial release" of an inefficient version of the invention/trade secret-- might not be fatal to your venture (could even mislead (or not)). Others who had the "old version" hopefully can't prove the necessary "efficiency" and "profit margins" (from new tweaks) required to be cconomically viable. You'd be "saved".
Limited Availability.
The future in biotech and life sciences is wide open; The fruit is ripe for the plucking. The competition is mostly weak; Many companies and investors waste massive amounts of money and hire some wrong people, a wrong mix of people, and are weak in management.[1]
Limited to High Potential disruptive or breakthrough projects
In academia, incremental papers with many authors can "get by" to hold on to a professorship,
or even in a Research Institute. But, publishing and PR remove most commercial value.
We can help an Institute nearing a big breakthrough, but our focus is disruptive commercial concept-exploitation with high ($billion) potential. An institute may license such valuable process, but should not have touted it around.
A “best fit” will be"
i) a secret concept for, ii) a do-able process or product that could be, iii) highly-scalable by high efficiencies, and iv) high margin with, v) a large under-served market-gap niche potential. These 5 factors determine overall potential.
Only high margins (profit ratio) can support an alternative to VC's/Angels or enable gov't grants intended for commercial exploitation. A possible atlernative for seed resources may be available through exchange of small "royalty interests", limited (all totalling less than 8 to 9% of sales), on future projected sales. Both types of funders-sources--- whether "royalty advance" method, versus conventional seed funding and (equity sales "rounds" (Offerings))--- are looking for high potential in a large growth niche.
An 8-9% sum of royalties to seed resource sources is limited to about 5 to 8 participants. That allows reserve of additional (or equity) for formal large start up and expansion financing (A, B, C "rounds") of conventional offerings (IFF margins appear over 40%)).
The difference is that pre-Seed and Seed stage are extremely difficult to raise funds from "investors" or VC's; The all-important IP cannot be discussed, advertised nor disclosed (unless very high-level generally).
VC's are looking for demonstrated execution nearing full-development toward production, sales and "start up", large pieces of ownership and control (large investors and VC's sit on the Board), and strong efforts to keep trade secrets... secret.
People and companies "in the business" may have a more flexible view, immediate
seed resources/funds, and long outlook and interests in your success.
NOTE--> (NONE of this is financial, investment, legal nor accounting advice nor asserted as fact, but merely opinion; Ask a professional; Do your own due diligence.)
Key to Funding or Resources:
Either way.... keys to Funding or Innovation success are--- 1) a proven concept,
2) big potential, and 3) a USA Top Phd Expert at your side, watching, helping, adding credibility, vouching, helping avoid mistakes, saving time and money, editing and helping funding presentations.
Key problems for Start-ups are facilities, labs, quality, secrecy, control and money.
Funders look for "proof", some execution (or depth), and "potential".
Showing feasibility and Proof of Concept, --- is a “chicken vs. egg first” problem, also due to requirement to keep secret. It is a balancing act of "stages" and steps of minimal disclosure.
The early bottom line missing piece… is... you need RESOURCES to prove the concept.
Sometimes we can help find a "partly-barter" source or short-term minor debt or strategic partnering arrangement (from someone wealthy or in the business (9 month renewable)) before moving to formal stages of funding by others (hopefully helping you avoid or delay some pitfalls and too early “selling of equity” (ownership) and assigning of all IP.
To aid Seed stage fund structures, science confidence and project management--- experts are needed. We continually screen for:
TopPhD-Consultants-tm (focused section) and TopScientists-tn (several fields).
These help us find resources and bio-business prospects.
We try to reach entrepreneur scientists and funders at crucial early stages.
WHAT AND WHEN:
We facilitate start up at the earliest possible stage-- through expansion stage---
by orienting you on key points, expectations, overview--- and
connecting talent, knowledge, ability, resources and funding, utilizing:
Top PhD-Consultants,
GroundFloorRoyaltyExchange-tn
SeedStageResources-tn
You as founder, at pre-seed or early stage, seeking resources and funding (via royalty and 9-month loan sourcing) should confirm concept potential while we help identify resources (by a small consultant commission or small percent (royalty)) on future sales. (thereby less-regulated, compared to major requirements, risks and pitfalls accompanying equity,/convertible bonds offerings (securities)).
Even for royalty advance (resources or cash) financing (exchange), the entrepreneur should prudently ensure that a fundng source is "sophisticated" (know i) some finance and biotech/ life science business), and ii) have capacity so risk versus net worth is under 10%.
Full risk disclosures and conservatve projections are ALWAYS required to sources who are still (even if outside the strict definition of "investors") expected to be or become somewhat “sophisticated”(under SEC definitions, though possibly not required#), by studying about science business, prudence and risks. Your citing risks can help reduce legal liabilities. (Ask a lawyer). Resource providers are usually also limited to 10% of Net worth unless "accredited".
These likely should sit on a "Board of Advisors" who give management pointers.
("participation" removes a claim of entirely "passive") (royalties and being active --- versus equity stock and "passive"--- may avoid being deemed "issuing securities" (very expensive filings and lawyers)). Ask a lawyer.
Scientists receiving royalty advance funding, resources or short term loans are expected to spend time informing themselves about securities definitions, rules and hazards of putting money or resources in risky early stage ventures--- especially selling ownership (equity stock), thereby often losing control yet assuming high legal fiduciary duties, and falling under strict regulations.
As explained in finance books and herein, medium to larger “deals” may require “rounds” of equity offerings to raise funds over $3 to $5 million+. Our TopPhD Consultants can assist presentations and planning on that journey.
A smart entrepreneur-scientist should study some of the business principles herein, and some parts of our www.Biz-Success.us site (a quick scan).
[1] Why do you think everything from health, medicine and therapeutics is so expensive? (and other reasons)
* Normally royalties on sales (and short-term smaller loans) are not classed as Securities (which have strict rules on disclosures, projections, audits and qualifications of "investors"); Sources like companies or Angels, regardless, to reduce risk-- should become "sophisticated" in the field.
(This is Not legal or financial advice)
By Guidance, finding Resources, a means of Royalty advance exchange, and
primarily our TopPhD-consultants-tm
Our Top Consultants can assist early & growth stage & mature corporations
in innovation, strategy and operations.
Our main functions are informing of hazards, helping guide, placing Top Consultants, showing alternatives, and helping find or acquire early resources: --
As primarily placing Biotech/ Life science consultants focused on concept, proof and early stage, and in innovation departments or spin off’s in established Life Science companies.
Consultants can help improve innovation and performance, with a record of scientific achievements in life science; We deliver customized solutions for needs of each client.
Whether strategic planning, market potential, science assessment, process efficiency-optimization, quality or change management--- our expertise can help your venture or project succeed. (There is no warranty on scientific nor busienss help, on success, for correctness, applicability, suitability, nor any other warranty; In any case, no refund shall exceed the last 2 hours of work; You must aise any issue or question promptly.)
We provide strategic research for Funders-investors and client-entrepreneurs in early-stage biotech-life science companies/Institutes-. This includes scientific assessment, due diligence, and analysis of market potential of new therapies and technologies, including improved efficiency (yield, purity).
We seek mutually beneficial relations with high potential ventures and turnarounds or newly innovative companies to successfully commercialize, develop or scale technologies that can improve people's lives and yield high returns to owners, funders-investors and licensees.
"It takes a lot of chemistry, math, cell biology, molecular biology, biochemistry, and biophysics knowledge to evaluate whether a concept or project's rationale is scientifically sound, truly innovative and economically viable." Dr. CW (Top Biophysics Consultant)
Convincing funders, corporations or proposal reviewers--- or breaking through a technical hurdle--- requires in-depth science help, and an outside expert vouching for sound science rationale and scalability.
Only quality deep science can innovate to a “disruptive” innovation level in the competitive biotech/ life science industry. Only highest skills and experience can help guide and correct labs or set up research departments to function smoothly with proper controls, quality and methods.
Only high, broad interdisciplinary skills, experience and knowledge that can synergistically integrate to leap frog to the next level.
You need a USA (or(UK) A-School PhD scientist to help guide your research project or help perfect your invention or document. An outside professional scientist avoids confirmation bias, social dynamics, organizational politics, funding pressure, and conflicts of interest.
· You want to know whether your great idea has a strong scientific rationale, and potential
· You need feedback on your paper or proposal.
· You're having difficulty ascertaining what an imporant research paper really says or implies.
· You're needing an innovative approach for a research breakthrough (you're too close to it).
· You need a plan or experiment design/ protocol written to test (prove out) a hypothesis.
· You need expert project management to take a concept to production and efficiency.
· Your biotech venture idea needs refining, viability review, proof of concept for a funding proposal, startup, or corporate approval.
Top PhD Consultants have a range of knowledge and experience to "ask the right questions the right way".
Our Top PhD's have degrees and/or postdocs from leading science Universities, like Johns Hopkins, Univ. of Texas, Univ. of Pensylvania, some with both Life science and Business training. Also.. have had Fellowships and continued courses, such as in AI, developed state of the art AI enhanced cell imaging, and worked on AI science math learning (training of AI) projects
An example portfolio includes
PhD in molecular biophysics (Honors Math and Biology majors under grad. ) with Business Degree, extensive research in cell biology, cell development, lung cancer, prostate cancer, blood, cell and serum-biologics therapies, protein customization, purification, sepration.
A decade of applied broad knowledge, over a decade of wet lab and research experience, toward innovation and research discoveries.
Range of work environments:
From: water treatment and habitat preservation to research on plant, animal and human cell development, including live human lung cancer cell research. developing revolutionary 3D AI enhanced cell imaging and cancer cell staging methods.
To: innovation labs and Research for major global companies, doing and guiding research in cancer and therapeutics, assisting management.
Working with leading cancer research facilities, collaborating in cell development research with pathology experts, leading a global team of AI experts, working with stored and live tissue beside USA's largest human cancer tissue bank,--- resulting in landmark discoveries and methods: breakthrough AI-enhanced 3D imaging of human lung cancer cell stages.
Lab and Innovation experience
Worked with non-profit environmental, pre-Startups... to large companies, toward high-potential discoveries: work with various instruments and techniques, skills to translate an idea into practical creation, refinement, process or production.
Deep biochemistry and molecular biophysics knowledge, utilizing latest instruments and methods... is invaluable to aid new concepts, startups, small and large companies. Molecular biophysics methods are used in small molecule early drug discovery and other areas (net energy and enthalpy drive reactions)
In innovation research, integrating technologies with vision and an eye to efficient production when discoveries begin to appear.
Refining and tweaking R & D, leading to quality, purity and efficient production—is how quality products and processes-- scalable to quantity and purity are achieved, as required in tomorrow’s competitive biotech world.
Such biochemistry and biophysics background and in-lab work enable solving problems, aiding discoveries and “vetting” biotech ventures. The methods and wide repertoire of skills provide a strong “independent outside view” of concepts, startups, new labs or facilities. Unlike many, our Consultants work with an eye toward scalability, efficiency and monetization.
Your company can benefit from such deep, broad knowledge portfolio:
Our main Consultant's discoveries included never-before-seen novel “processes” (tubes or channels) between cells, dimiished in cancer cells. This has substantially obsoleted some long-held theories and advanced cancer cell imaging techniques and staging standards.
Such Focus (practice) likely fits your needs from idea, project or venture--- to success.
Benefit from TopPhD-consultants' broad skills and knowledge, at reasonable rates.
--------- Contact us today with your questions or need.
Limited Availability
Biotech Start, (herein Biotech Start or "BioStart" section of Buyers' Group (us), hereby states and you (being yourself, your agent, assign or organization as prospect or client of "Consultant" (referred by us)) agree by any use of information from this website or such associated Consultant referred by BioStart--- to the following Terms and Conditions, on behalf of yourself and any entity under which you may use or receive any information herefrom of or by negotiating with or engaging service from Consultant:
Nothing on this Website nor any discussion of possibilities is either Financial, investment nor Legal advice. Consult a Professsional.
Limitation of Liability
Biotech-Start section of Buyers' Group (herein "Bio-start") Consulting, it's owners, assigns, agents and any Affiliated person or Consultant shall not be liable for any loss, injury, claim, liability, or damage of any kind resulting in any way from (i) any errors in or omissions from the Web site or information or service obtained by you from any person or Consultant associated with BioStart , (ii) the content contained on this Web site or provided by the Consultant, or (iii) any delay, deficiency, mistake, fault or failure in performance as to services, information or suggestions provided to you, whatsoever.
These pages and associated Consultant's statements or conclusions--- MAY CONTAIN ERRORS and/or may be entirely or partly not suitable for your situation or your problem(s).
ALL information herein and by asscocated Consultants is PROVIDED AS IS, with any faults or errors that may occur.
Do not rely solely on the information in this website and by an associated Consultant.
All discused website information IS GENERAL, and observations or suggestions, NOT ADVICE for your specific situation.
None of the information here or by Consultant is guaranteed. Confirm and do your own due diligence.
USE OF THIS WEBSITE and CONSULTANT SERVICES is without warranty, all information to be confirmed by you:
Your use of this website and/or associate Consultant signifies and constitutes your full understanding and agreement that:
The information on this website is for general informational purposes only.
Biotech Start and Buyers' Group make no representation or warranty, express or implied, regarding the content accuracy, suitability or correctness.
The content on this website does not constitute professional advice.
This website may contain links to third-party websites or content which are soley the responsibility of the owners thereof .
Biotech Start/Buyers' Group does not endorse or recommend third-party websites, products, or services, and base our own opinion on information and credentials passed along by consultant, by conversation and evaluation, and extent of references available, as to the general calibre of Top Consultants but only as provided by Consultant, and therefore you, client or your organinzation should perform your own due diligence.
Buyers' Group does not guarantee specific results or outcomes, and all information and consulting services are provided AS IS, along with any
faults, errors, pertinent omissions or defects.
You agree to check and perform your own due diligence in all matters and consulting services obtained from or through Biotech Start section of Buyers' Group. All content on this website is the property of owner, except for cite or credits to others.
Buyers' Group may update or modify information on this website without prior notice.
Users of this site and/or of Consultants-- agree to indemnify and hold harmless Buyers Group and R. Sandlin, agents, assigns, successors and associates and associated Consultants from any and all claims arising from use of this website and information provided by Consultant in any manner.
This disclaimer is governed by the laws of Texas
Other than these terms, this website establishes NO direct consultant-client relationship. (any such relation would or may be done via agreement between you and a chosen Consultant referred hereby).
CONFIDENTIALITY: Biotech-Start and Buyers' Group principal(s) will not normally be informed of most details of your concept, your narrow niche, and similar, but only high level and overview (except in event of a controversy on such if such might occur). If our referred Consultant agrees to do work and there is no apparent conflict with the Consultant's own prior IP or that of a Biotech-Start/Buyers' Group principal or another client of either (Consultant nor Biotech-Start/Buyers' Group principal), then we and Consultant will agree to keep your concept in confidence--- as long as no conflict is apparent or occurs. We urge that you and Scientist-Consultant sign a fairly standard NDA before you reveal fine details of concept, advantages, and how it is distinguished, novel, unique, its' hypothesis, niche, methods, technology, etc.); Though referred scientist has pledged confidentiality of clien's unique, novel IP, the consulting relationship, and your disclosures are to and with the Consultant, thereby that agreement and your engagement agreement are primarily between you and such referred Consultant.
After preliminary high-level disclosure, in steps, of a concept you bring, of field, industry and/or market (general, not sub-segment nor niche)
If you have any questions in regard any of these terms, you must immediately make such known via the Contact page, so we can clarify or help you understand. If you still do not understand any part hereof, consult an attorney to go over it with you.
Overall, we strive to connect with reputable Consultants, whose credentials have been examined, and try generally to provide good service, as possible.
Biotech Start
Copyright © 2024 Biotech Start - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.